Last reviewed 2026-04-20 · How we verify

Etaproctene (PREDNISOLAMATE)

Phase 2 active Small molecule

Etaproctene (generic name: PREDNISOLAMATE) is a Corticosteroid drug. It is currently in Phase 2 development.

Etaproctene works by binding to glucocorticoid receptors in the body, which then suppresses the immune system and reduces inflammation.

Etaproctene, also known as Prednisolamate, is a corticosteroid small molecule drug. It is used to treat various conditions, although its specific indications are not provided. As a corticosteroid, it works by suppressing the immune system and reducing inflammation. The commercial status of Etaproctene is unknown, and it may be patented or generic. Key safety considerations include the potential for side effects associated with corticosteroid use.

Likelihood of approval

16.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Immunology slight uplift +1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	PREDNISOLAMATE
Drug class	Corticosteroid
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 2

Mechanism of action

Imagine your immune system is like a fire alarm that goes off when it senses danger. Corticosteroids like Etaproctene are like a fire alarm silencer that reduces the alarm's sensitivity, helping to calm down the immune response and reduce inflammation. This can be helpful for treating conditions like arthritis or asthma, but it can also increase the risk of infections and other side effects.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Etaproctene CI brief — competitive landscape report
Etaproctene updates RSS · CI watch RSS

Frequently asked questions about Etaproctene

What is Etaproctene?

Etaproctene (PREDNISOLAMATE) is a Corticosteroid drug.

How does Etaproctene work?

Etaproctene works by binding to glucocorticoid receptors in the body, which then suppresses the immune system and reduces inflammation.

What is the generic name of Etaproctene?

PREDNISOLAMATE is the generic (nonproprietary) name of Etaproctene.

What drug class is Etaproctene in?

Etaproctene belongs to the Corticosteroid class. See all Corticosteroid drugs at /class/corticosteroid.

What development phase is Etaproctene in?

Etaproctene is in Phase 2.

Drug class: All Corticosteroid drugs
Therapeutic area: All drugs in Immunology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing